Pesquisa | Secretaria de Estado da Saúde

1.

Spatial predictors of immunotherapy response in triple-negative breast cancer.

Wang, Xiao Qian; Danenberg, Esther; Huang, Chiun-Sheng; Egle, Daniel; Callari, Maurizio; Bermejo, Begoña; Dugo, Matteo; Zamagni, Claudio; Thill, Marc; Anton, Anton; Zambelli, Stefania; Russo, Stefania; Ciruelos, Eva Maria; Greil, Richard; Gyorffy, Balázs; Semiglazov, Vladimir; Colleoni, Marco; Kelly, Catherine M; Mariani, Gabriella; Del Mastro, Lucia; Biasi, Olivia; Seitz, Robert S; Valagussa, Pinuccia; Viale, Giuseppe; Gianni, Luca; Bianchini, Giampaolo; Ali, H Raza.

Nature ; 621(7980): 868-876, 2023 Sep.

Artigo Inglês | MEDLINE | ID: mdl-37674077

2.

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

Bardia, Aditya; Hurvitz, Sara A; Tolaney, Sara M; Loirat, Delphine; Punie, Kevin; Oliveira, Mafalda; Brufsky, Adam; Sardesai, Sagar D; Kalinsky, Kevin; Zelnak, Amelia B; Weaver, Robert; Traina, Tiffany; Dalenc, Florence; Aftimos, Philippe; Lynce, Filipa; Diab, Sami; Cortés, Javier; O'Shaughnessy, Joyce; Diéras, Véronique; Ferrario, Cristiano; Schmid, Peter; Carey, Lisa A; Gianni, Luca; Piccart, Martine J; Loibl, Sibylle; Goldenberg, David M; Hong, Quan; Olivo, Martin S; Itri, Loretta M; Rugo, Hope S.

N Engl J Med ; 384(16): 1529-1541, 2021 04 22.

Artigo Inglês | MEDLINE | ID: mdl-33882206

3.

Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy.

Licata, Luca; Barreca, Marco; Galbardi, Barbara; Dugo, Matteo; Viale, Giulia; Gyorffy, Balàzs; Karn, Thomas; Pusztai, Lajos; Gianni, Luca; Callari, Maurizio; Bianchini, Giampaolo.

Br J Cancer ; 129(12): 2025-2033, 2023 12.

Artigo Inglês | MEDLINE | ID: mdl-37935787

4.

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.

Gianni, Luca; Bisagni, Giancarlo; Colleoni, Marco; Del Mastro, Lucia; Zamagni, Claudio; Mansutti, Mauro; Zambetti, Milvia; Frassoldati, Antonio; De Fato, Raffaella; Valagussa, Pinuccia; Viale, Giuseppe.

Lancet Oncol ; 19(2): 249-256, 2018 02.

Artigo Inglês | MEDLINE | ID: mdl-29326029

5.

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.

Viala, Marie; Vinches, Marie; Alexandre, Marie; Mollevi, Caroline; Durigova, Anna; Hayaoui, Nadia; Homicsko, Krisztian; Cuenant, Alice; Gongora, Céline; Gianni, Luca; Tosi, Diego.

Br J Cancer ; 118(5): 679-697, 2018 03 06.

Artigo Inglês | MEDLINE | ID: mdl-29438365

6.

HER2-positive breast cancer.

Loibl, Sibylle; Gianni, Luca.

Lancet ; 389(10087): 2415-2429, 2017 Jun 17.

Artigo Inglês | MEDLINE | ID: mdl-27939064

7.

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.

Cameron, David; Piccart-Gebhart, Martine J; Gelber, Richard D; Procter, Marion; Goldhirsch, Aron; de Azambuja, Evandro; Castro, Gilberto; Untch, Michael; Smith, Ian; Gianni, Luca; Baselga, Jose; Al-Sakaff, Nedal; Lauer, Sabine; McFadden, Eleanor; Leyland-Jones, Brian; Bell, Richard; Dowsett, Mitch; Jackisch, Christian.

Lancet ; 389(10075): 1195-1205, 2017 03 25.

Artigo Inglês | MEDLINE | ID: mdl-28215665

8.

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.

Diéras, Véronique; Miles, David; Verma, Sunil; Pegram, Mark; Welslau, Manfred; Baselga, José; Krop, Ian E; Blackwell, Kim; Hoersch, Silke; Xu, Jin; Green, Marjorie; Gianni, Luca.

Lancet Oncol ; 18(6): 732-742, 2017 06.

Artigo Inglês | MEDLINE | ID: mdl-28526536

9.

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.

Bianchini, Giampaolo; Kiermaier, Astrid; Bianchi, Giulia Valeria; Im, Young-Hyuck; Pienkowski, Tadeusz; Liu, Mei-Ching; Tseng, Ling-Ming; Dowsett, Mitch; Zabaglo, Lila; Kirk, Sarah; Szado, Tania; Eng-Wong, Jennifer; Amler, Lukas C; Valagussa, Pinuccia; Gianni, Luca.

Breast Cancer Res ; 19(1): 16, 2017 02 09.

Artigo Inglês | MEDLINE | ID: mdl-28183321

10.

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

Gianni, Luca; Pienkowski, Tadeusz; Im, Young-Hyuck; Tseng, Ling-Ming; Liu, Mei-Ching; Lluch, Ana; Staroslawska, Elzbieta; de la Haba-Rodriguez, Juan; Im, Seock-Ah; Pedrini, Jose Luiz; Poirier, Brigitte; Morandi, Paolo; Semiglazov, Vladimir; Srimuninnimit, Vichien; Bianchi, Giulia Valeria; Magazzù, Domenico; McNally, Virginia; Douthwaite, Hannah; Ross, Graham; Valagussa, Pinuccia.

Lancet Oncol ; 17(6): 791-800, 2016 Jun.

Artigo Inglês | MEDLINE | ID: mdl-27179402

11.

Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.

Reni, Michele; Balzano, Gianpaolo; Zanon, Silvia; Passoni, Paolo; Nicoletti, Roberto; Arcidiacono, Paolo Giorgio; Pepe, Gino; Doglioni, Claudio; Fugazza, Clara; Ceraulo, Domenica; Falconi, Massimo; Gianni, Luca.

Br J Cancer ; 115(3): 290-6, 2016 Jul 26.

Artigo Inglês | MEDLINE | ID: mdl-27404453

12.

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.

Metzger-Filho, Otto; de Azambuja, Evandro; Procter, Marion; Krieguer, Magalie; Smith, Ian; Baselga, Jose; Cameron, David; Untch, Michael; Jackisch, Christian; Bell, Richard; Gianni, Luca; Goldhirsch, Aron; Piccart, Martine; Gelber, Richard D.

Breast Cancer Res Treat ; 155(1): 127-32, 2016 Jan.

Artigo Inglês | MEDLINE | ID: mdl-26708471

13.

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Cortazar, Patricia; Zhang, Lijun; Untch, Michael; Mehta, Keyur; Costantino, Joseph P; Wolmark, Norman; Bonnefoi, Hervé; Cameron, David; Gianni, Luca; Valagussa, Pinuccia; Swain, Sandra M; Prowell, Tatiana; Loibl, Sibylle; Wickerham, D Lawrence; Bogaerts, Jan; Baselga, Jose; Perou, Charles; Blumenthal, Gideon; Blohmer, Jens; Mamounas, Eleftherios P; Bergh, Jonas; Semiglazov, Vladimir; Justice, Robert; Eidtmann, Holger; Paik, Soonmyung; Piccart, Martine; Sridhara, Rajeshwari; Fasching, Peter A; Slaets, Leen; Tang, Shenghui; Gerber, Bernd; Geyer, Charles E; Pazdur, Richard; Ditsch, Nina; Rastogi, Priya; Eiermann, Wolfgang; von Minckwitz, Gunter.

Lancet ; 384(9938): 164-72, 2014 Jul 12.

Artigo Inglês | MEDLINE | ID: mdl-24529560

14.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Verma, Sunil; Miles, David; Gianni, Luca; Krop, Ian E; Welslau, Manfred; Baselga, José; Pegram, Mark; Oh, Do-Youn; Diéras, Véronique; Guardino, Ellie; Fang, Liang; Lu, Michael W; Olsen, Steven; Blackwell, Kim.

N Engl J Med ; 367(19): 1783-91, 2012 Nov 08.

Artigo Inglês | MEDLINE | ID: mdl-23020162

15.

The immune system and response to HER2-targeted treatment in breast cancer.

Bianchini, Giampaolo; Gianni, Luca.

Lancet Oncol ; 15(2): e58-68, 2014 Feb.

Artigo Inglês | MEDLINE | ID: mdl-24480556

16.

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

André, Fabrice; O'Regan, Ruth; Ozguroglu, Mustafa; Toi, Masakazu; Xu, Binghe; Jerusalem, Guy; Masuda, Norikazu; Wilks, Sharon; Arena, Francis; Isaacs, Claudine; Yap, Yoon-Sim; Papai, Zsuzsanna; Lang, Istvan; Armstrong, Anne; Lerzo, Guillermo; White, Michelle; Shen, Kunwei; Litton, Jennifer; Chen, David; Zhang, Yufen; Ali, Shyanne; Taran, Tetiana; Gianni, Luca.

Lancet Oncol ; 15(6): 580-91, 2014 May.

Artigo Inglês | MEDLINE | ID: mdl-24742739

17.

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

Gianni, Luca; Eiermann, Wolfgang; Semiglazov, Vladimir; Lluch, Ana; Tjulandin, Sergei; Zambetti, Milvia; Moliterni, Angela; Vazquez, Federico; Byakhov, Mikhail J; Lichinitser, Mikhail; Climent, Miguel Angel; Ciruelos, Eva; Ojeda, Belen; Mansutti, Mauro; Bozhok, Alla; Magazzù, Domenico; Heinzmann, Dominik; Steinseifer, Jutta; Valagussa, Pinuccia; Baselga, Jose.

Lancet Oncol ; 15(6): 640-7, 2014 May.

Artigo Inglês | MEDLINE | ID: mdl-24657003

18.

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.

Perez, Edith A; Hurvitz, Sara A; Amler, Lukas C; Mundt, Kirsten E; Ng, Vivian; Guardino, Ellie; Gianni, Luca.

Breast Cancer Res ; 16(3): R50, 2014 May 23.

Artigo Inglês | MEDLINE | ID: mdl-24887458

19.

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Goldhirsch, Aron; Gelber, Richard D; Piccart-Gebhart, Martine J; de Azambuja, Evandro; Procter, Marion; Suter, Thomas M; Jackisch, Christian; Cameron, David; Weber, Harald A; Heinzmann, Dominik; Dal Lago, Lissandra; McFadden, Eleanor; Dowsett, Mitch; Untch, Michael; Gianni, Luca; Bell, Richard; Köhne, Claus-Henning; Vindevoghel, Anita; Andersson, Michael; Brunt, A Murray; Otero-Reyes, Douglas; Song, Santai; Smith, Ian; Leyland-Jones, Brian; Baselga, Jose.

Lancet ; 382(9897): 1021-8, 2013 Sep 21.

Artigo Inglês | MEDLINE | ID: mdl-23871490

20.

Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.

Bahleda, Rastislav; Sessa, Cristiana; Del Conte, Gianluca; Gianni, Luca; Capri, Giuseppe; Varga, Andrea; Oprea, Corina; Daglish, Byzance; Hospitel, Marie; Soria, Jean-Charles.

Invest New Drugs ; 32(6): 1188-96, 2014 Dec.

Artigo Inglês | MEDLINE | ID: mdl-24898305

Secretaria de Estado da Saúde - BVS

Rede de Informação e Conhecimento

Sua seleção (0)

Formato de exportação:

Exportar: